Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancer

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

“…The few neoadjuvant studies conducted to-date with single agent doxorubicin or docetaxel reported a very similar activity [23][24][25]. In our trial, ER negative status was a strong but unspecific predictor of sensitivy to either docetaxel and doxorubicine.…”

Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer and comparison with anthracycline-based chemotherapies: Eight-year experience from single centre

“…Single agent docetaxel has produced pCR rates of 16-20% andnical complete responses of 18% to more than 25%. [13,14,23,24] In combination with anthracyclines pCR rates of 10% to >20% are reported depending upon the stages of tumor included in that particular study. [17,[25][26][27][28][29] As most of the trials are retrospective, have small sample size and include a heterogeneous group of patients, it is not possible to directly compare the results but the pCR and cCR in our study are in accordance with results previously reported in the literature.…”